References
- Qureshi SA, McGilveray IJ. (1999). Typical variability in drug dissolution testing: Study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product. Eur J Pharm Sci, 7:249–258.
- Shah VP, Konecny JJ, Everett RL, McCullough B, Noorizadeh AC, Skelly JP. (1989). In vitro dissolution profile of water-insoluble drug dosage forms in the presence of surfactants. Pharm Res, 6:612–618.
- U.S.P 23 rev. (1995). US Pharmacopoeia Convention, Rockville, M.D, p. 267, 429 and 722.
- Löbenberg R, Krämer J, Shah VP, Amidon GL, Dressman JB. (2000). Dissolution testing as a prognostic tool for oral drug absorption: Dissolution behavior of glibenclamide. Pharm Res, 17:439–444.
- Rossi L, Costa B, Tomei R, Franceschini L, Castello C, Carbonieri E et al. (2002). Antihypertensive effects of lacidipine during effort in mild to moderate hypertension. J Cardiovasc Pharmacol, 40:315–321.
- Franc V, et al. (1995). Process for preparation of solid dispersions and deposits as well as of medicinal forms with dihydropyridine type calcium antagonists. WO patent 6, 95/08987.
- Sun PC, Chiu CT (2006). Composition of increasing dissolution rate for lacidipine tablet and preparation method thereof. TW, R.O.C., TW20040141808 20041231, TWI265813 (B): 4–10.
- Siewert M. (1993). Perspectives of in vitro dissolution tests in establishing in vivo/in vitro correlations. Eur J Drug Metab Pharmacokinet, 18:7–18.
- Lo′pez JA, Mart′ınez V, Alonso RM, Jime′nez RM. (2000). High-performance liquid chromatography with amperometric detection applied to the screening of 1,4-dihydropyridines in human plasma. J Chromatogr A, 870:105–114.
- Gannu R, Yamsani VV, Palem CR, Yamsani SK, Yamsani MR. (2009). Development of high performance liquid chromatography method for lacidipine in rabbit serum: Application to pharmacokinetic study. Anal Chim Acta, 632:278–283.
- Tang J, Zhu R, Zhao R, Cheng G, Peng W. (2008). Ultra-performance liquid chromatography-tandem mass spectrometry for the determination of lacidipine in human plasma and its application in a pharmacokinetic study. J Pharm Biomed Anal, 47:923–928.
- Tang L, Khan SU, Muhammad NA. (2001). Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm Dev Technol, 6:531–540.
- Swanepoel E, Liebenberg W, Devarakonda B, de Villiers MM. (2003). Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences. Pharmazie, 58:117–121.
- Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413–420.
- Dressman JB, Reppas C. (2000). In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci, 11:73–80.
- Ansari M, Kazemipour M, Talebnia J. (2004). The development and validation of a dissolution method for clomipramine solid dosage forms. Dissol Technol, 11:16–24.